FDA's patient-preference guidance now spans the lifecycle

A 2016 guidance built around three submission types

FDA's original guidance, Patient Preference Information — Voluntary Submission, Review in Premarket Approval Applications, Humanitarian Device Exemption Applications, and De Novo Requests, and Inclusion in Decision Summaries and Device Labeling, finalized August 24, 2016, grew out of a Patient Preference Initiative the agency launched in 2013 and the Patient Engagement Advisory Committee it convened for the first time in September 2015. The guidance named exactly what its own title promised: patient preference information, PPI, that a sponsor chose to submit could inform FDA's benefit-risk determination in a PMA, an HDE application, or a De Novo request, and FDA committed to describing PPI's role in the resulting decision summary and, where it mattered, in the device's own labeling. A 510(k), an IDE application, and a Breakthrough Device request all sat outside the guidance's own stated scope.

The total product life cycle version

On March 30, 2026, FDA finalized a successor guidance, Incorporating Voluntary Patient Preference Information over the Total Product Life Cycle, replacing the 2016 document outright rather than supplementing it. The title change is the content change: PPI isn't scoped to three premarket submission types anymore. FDA's stated intent is to consider voluntarily submitted PPI across a device's entire regulatory life, naming IDE applications, Breakthrough Device designation requests, and 510(k) submissions explicitly, alongside the administrative, compliance, and enforcement decisions FDA makes about a device once it's already on the market.

Voluntary didn't change; the invitation got wider

Nothing about the 2026 guidance makes PPI a required element of any submission it now names. An IDE application already carries its own required contents independent of whatever preference evidence a sponsor chooses to attach, and a 510(k)'s substantial-equivalence showing doesn't acquire a new mandatory element just because FDA says it will now read PPI where a sponsor supplies it. What changed is the range of decisions FDA is telling sponsors it will actually weigh PPI for. A sponsor pursuing Breakthrough designation, deciding whether a preference study is worth running before an IDE, or responding to a question about a device already on the market now has a named reason to submit PPI where the 2016 guidance gave none.

What a preference study still has to earn

Widening the list of venues doesn't touch the other half of the 2016 guidance that carries into its replacement: a submission still has to be a well-designed study of an identified patient population's own preferences, not a sponsor's assertion about what patients probably think. The qualities FDA named in 2016 — a clearly defined target population, a method actually suited to measuring preference rather than a different outcome entirely, and a design free of the kind of bias that would make the result unusable for a regulatory decision — carry forward into a guidance that now reads PPI in more places, not one that reads it more loosely. A thin survey attached to a 510(k) because the new guidance mentions 510(k)s by name hasn't earned any more weight than the same survey would have earned attached to a PMA under the old one.

Where this meets the file

A PPI tracking record needs the submission type it was filed against named as its own field, not folded into a single “patient preference data: yes” box, since FDA's own willingness to weigh that evidence now depends on which total-product-life-cycle venue a sponsor is actually filing in. A benefit-risk and patient-preference worksheet built around that structure, alongside the launch catalog's other premarket templates, is previewed there now. If your program has tracked PPI's role differently, the shelf takes that correction directly.